Intestinal Research

IBD
Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation: Brigida Barberio, Edoardo Vincenzo Savarino, Timothy Card, Cristina Canova, Francesco Baldisser, Alessandro Gubbiotti, Davide Massimi, Matteo Ghisa, Fabiana Zingone; Intest Res. 2022;20(1):114-123. Published online August 4, 2021; DOI: https://doi.org/10.5217/ir.2021.00037
Web of Science 10 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Inflammatory bowel diseases
Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria: Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag; Intest Res. 2019;17(3):340-348. Published online May 31, 2019; DOI: https://doi.org/10.5217/ir.2019.00012
Web of Science 15 Crossref 19; Full text PubReader ePub PDF

Risk of surgery in patients with stricturing type of Crohn’s disease at the initial diagnosis: a single center experience: Yuji Maehata, Yutaka Nagata, Tomohiko Moriyama, Yuichi Matsuno, Atsushi Hirano, Junji Umeno, Takehiro Torisu, Tatsuya Manabe, Takanari Kitazono, Motohiro Esaki; Intest Res. 2019;17(3):357-364. Published online February 21, 2019; DOI: https://doi.org/10.5217/ir.2018.00107
Web of Science 9 Crossref 9; Full text PubReader ePub PDF

Search